目的研究伊立替康(CPT-11)、5-氟尿嘧啶(5-Fu)、亚叶酸钙(CF)联合组成的FOLFIRI方案治疗晚期大肠癌的近期疗效和毒副作用。方法对25例初治或复治晚期大肠癌患者采用伊立替康180 mg/m2,静脉滴注1.5 h,d1;CF 200 mg/m2,静脉滴注d1～d2;5-Fu 1400～1800 mg/m2,持续静脉滴注46 h,d1～d2。14 d为1个周期,行4个周期治疗后判定疗效。结果 23例患者可评价疗效及不良反应,总有效率为39.1%,不良反应主要表现为骨髓抑制白细胞减少、恶心、呕吐、延迟性腹泻、急性胆碱能综合征等,程度较轻,无化疗相关死亡。结论 FOLFIRI方案一线治疗晚期大肠癌疗效肯定,毒副作用能耐受。 Objective To investigate the short-term curative effect and side effects of FOLFIRI regimen consisting of irinotecan (CPT-11), 5-fluorouracil (5-Fu) and leucovorin (CF) in the treatment of advanced colorectal cancer. Methods Twenty-five patients with newly diagnosed or re-treated advanced colorectal cancer were treated with irinotecan 180 mg / m2, intravenous drip for 1.5 h, d1; CF 200 mg / m2, intravenous drip d1 ~ d2; / m2, continuous intravenous infusion of 46 h, d1 ~ d2.14 d for a cycle of 4 cycles after treatment to determine the efficacy. Results Twenty-three patients were evaluated for efficacy and adverse reactions, with a total effective rate of 39.1%. Adverse reactions mainly included myelosuppression leukopenia, nausea, vomiting, delayed diarrhea and acute cholinergic syndrome, Related deaths. Conclusion The first-line FOLFIRI regimen is effective in treating advanced colorectal cancer with tolerable side effects.